Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LXR-623 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Tolerability |
Not provided
Not provided
Inclusion:
Exlcusion:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lincoln | Nebraska | 68502 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40695410 | Derived | Richartz J, Yam SC, Zhan N, Schepers M, Tiane A, Mulder MT, Wens I, Vanmierlo T. Liver X receptors: A therapeutic target in demyelinating disorders. Pharmacol Res. 2025 Sep;219:107861. doi: 10.1016/j.phrs.2025.107861. Epub 2025 Jul 20. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C547927 | 2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided